SHSE:600664's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.025 * Ranked among companies with meaningful Forward Dividend Yield % only.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Harbin Pharmaceutical Group Co was 114.00% per year. The lowest was -47.00% per year. And the median was 6.45% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Harbin Pharmaceutical Group Co (SHSE:600664) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Harbin Pharmaceutical Group Co Forward Dividend Yield % Related Terms
SHSE:600664 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Pharmaceutical Group Co's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harbin Pharmaceutical Group Co Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harbin Pharmaceutical Group Co's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Harbin Pharmaceutical Group Co's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Harbin Pharmaceutical Group Co (SHSE:600664) has a Forward Dividend Yield % of 0.00% as of Jul. 05, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Harbin Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Harbin Pharmaceutical Group Co ranks #999999 out of 506 companies in the Drug Manufacturers industry.
Is Harbin Pharmaceutical Group Co's Forward Dividend Yield % too high?
Harbin Pharmaceutical Group Co's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Harbin Pharmaceutical Group Co ranks #999999 out of 506 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Harbin Pharmaceutical Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harbin Pharmaceutical Group Co's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Harbin Pharmaceutical Group Co ranks #999999 out of 506 companies for Forward Dividend Yield %. This places Harbin Pharmaceutical Group Co in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Harbin Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harbin Pharmaceutical Group Co's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harbin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co (SHSE:600664) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥3.51, compared to a current price of ¥3.14 — trading 10.5% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Harbin Pharmaceutical Group Co's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Harbin Pharmaceutical Group Co (SHSE:600664), the current Forward Dividend Yield % is 0.00% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harbin Pharmaceutical Group Co (SHSE:600664) Overvalued in 2026?
Based on GuruFocus' analysis, Harbin Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥3.14 is trading 10.5% below its estimated GF Value™ of ¥3.51.
GuruFocus considers Harbin Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:600664:
Forward Dividend Yield %: 0.00%
GF Value™: ¥3.51 vs. price of ¥3.14 (10.5% below fair value)
No single metric tells the full story. See the SHSE:600664 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harbin Pharmaceutical Group Co Business Description
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
78GF Score
Get the complete analysis for SHSE:600664
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600664 has been successfully added to your 